Chengdu Easton Biopharmaceuticals Inkomsten in het verleden
Verleden criteriumcontroles 2/6
Chengdu Easton Biopharmaceuticals has been growing earnings at an average annual rate of 13.9%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been growing at an average rate of 7.1% per year. Chengdu Easton Biopharmaceuticals's return on equity is 9.3%, and it has net margins of 19.1%.
Belangrijke informatie
13.9%
Groei van de winst
9.1%
Groei van de winst per aandeel
| Pharmaceuticals Groei van de industrie | 10.9% |
| Inkomstengroei | 7.1% |
| Rendement op eigen vermogen | 9.3% |
| Nettomarge | 19.1% |
| Laatste winstupdate | 30 Sep 2024 |
Recente prestatie-updates uit het verleden
Concerns Surrounding Chengdu Easton Biopharmaceuticals' (SHSE:688513) Performance
Nov 01
Why Chengdu Easton Biopharmaceuticals' (SHSE:688513) Shaky Earnings Are Just The Beginning Of Its Problems
May 01Recent updates
Concerns Surrounding Chengdu Easton Biopharmaceuticals' (SHSE:688513) Performance
Nov 01There Is A Reason Chengdu Easton Biopharmaceuticals Co., Ltd.'s (SHSE:688513) Price Is Undemanding
Jul 23Why Chengdu Easton Biopharmaceuticals' (SHSE:688513) Shaky Earnings Are Just The Beginning Of Its Problems
May 01Chengdu Easton Biopharmaceuticals Co., Ltd.'s (SHSE:688513) Share Price Matching Investor Opinion
Mar 26Opbrengsten en kosten
Hoe Chengdu Easton Biopharmaceuticals geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Sep 24 | 1,307 | 250 | 556 | 257 |
| 30 Jun 24 | 1,231 | 242 | 531 | 240 |
| 31 Mar 24 | 1,154 | 241 | 496 | 242 |
| 31 Dec 23 | 1,117 | 227 | 483 | 237 |
| 30 Sep 23 | 1,123 | 245 | 494 | 234 |
| 30 Jun 23 | 1,150 | 243 | 534 | 237 |
| 31 Mar 23 | 1,179 | 254 | 559 | 235 |
| 31 Dec 22 | 1,171 | 247 | 566 | 230 |
| 30 Sep 22 | 1,147 | 242 | 561 | 217 |
| 30 Jun 22 | 1,100 | 250 | 544 | 205 |
| 31 Mar 22 | 1,071 | 243 | 542 | 203 |
| 31 Dec 21 | 1,023 | 232 | 526 | 200 |
| 30 Sep 21 | 1,023 | 239 | 552 | 191 |
| 30 Jun 21 | 986 | 209 | 539 | 181 |
| 31 Mar 21 | 967 | 191 | 546 | 169 |
| 31 Dec 20 | 922 | 178 | 528 | 153 |
| 30 Sep 20 | 942 | 139 | 573 | 148 |
| 30 Jun 20 | 907 | 115 | 576 | 146 |
| 31 Mar 20 | 886 | 100 | 579 | 144 |
| 31 Dec 19 | 947 | 109 | 624 | 156 |
| 31 Dec 18 | 769 | 135 | 458 | 124 |
| 31 Dec 17 | 476 | 64 | 276 | 77 |
| 30 Jun 16 | 250 | 44 | 110 | 0 |
| 31 Mar 16 | 245 | 41 | 99 | 0 |
| 31 Dec 15 | 241 | 38 | 87 | 0 |
| 01 Jan 15 | 209 | 29 | 70 | 0 |
| 31 Dec 13 | 162 | 15 | 54 | 0 |
Kwaliteitswinsten: 688513 has a large one-off gain of CN¥64.5M impacting its last 12 months of financial results to 30th September, 2024.
Groeiende winstmarge: 688513's current net profit margins (19.1%) are lower than last year (21.8%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: 688513's earnings have grown by 13.9% per year over the past 5 years.
Versnelling van de groei: 688513's earnings growth over the past year (2.1%) is below its 5-year average (13.9% per year).
Winst versus industrie: 688513 earnings growth over the past year (2.1%) exceeded the Pharmaceuticals industry -1.2%.
Rendement op eigen vermogen
Hoge ROE: 688513's Return on Equity (9.3%) is considered low.